(Q28265584)

1

0 references

William J Boyle

2

0 references

W Scott Simonet

3

0 references

Paul J Kostenuik

4

0 references

William C Dougall

5

0 references

John K Sullivan

6

0 references

Javier San Martin

7

0 references

Roger Dansey

Nature Reviews Drug Discovery

8

0 references

language of work or name

English

0 references

publication date

May 2012

0 references

published in

0 references

volume

11

0 references

issue

5

0 references

page(s)

401-19

0 references

cites work

Sequence identification of 2,375 human brain genes

1 reference

3,400 new expressed sequence tags identify diversity of transcripts in human brain

31 March 2020

1 reference

Rapid cDNA sequencing (expressed sequence tags) from a directionally cloned human infant brain cDNA library

31 March 2020

1 reference

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

31 March 2020

1 reference

Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNFalpha, but the dimer is a more potent TNF inhibitor

31 March 2020

1 reference

The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death

31 March 2020

1 reference

The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells

31 March 2020

1 reference

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis

31 March 2020

1 reference

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

31 March 2020

1 reference

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

31 March 2020

1 reference

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

31 March 2020

1 reference

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

31 March 2020

1 reference

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells

31 March 2020

1 reference

RANK is essential for osteoclast and lymph node development

31 March 2020

1 reference

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

31 March 2020

1 reference

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

31 March 2020

1 reference

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

31 March 2020

1 reference

Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature

31 March 2020

1 reference

Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase

31 March 2020

1 reference

Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand

31 March 2020

1 reference

Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells

31 March 2020

1 reference

Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis

31 March 2020

1 reference

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

31 March 2020

1 reference

Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity

31 March 2020

1 reference

Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation

31 March 2020

1 reference

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

31 March 2020

1 reference

Structural and functional insights of RANKL-RANK interaction and signaling

31 March 2020

1 reference

The signaling adaptors and pathways activated by TNF superfamily

31 March 2020

1 reference

TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology.

31 March 2020

1 reference

Osteoclast differentiation and activation

31 March 2020

1 reference

Regulatory roles and molecular signaling of TNF family members in osteoclasts

31 March 2020

1 reference

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling

31 March 2020

1 reference

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

31 March 2020

1 reference

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo

31 March 2020

1 reference

Self-assembled RANK induces osteoclastogenesis ligand-independently.

31 March 2020

1 reference

Signal peptide mutations in RANK prevent downstream activation of NF-κB.

31 March 2020

1 reference

Role of osteoblasts in hormonal control of bone resorption—A hypothesis

31 March 2020

1 reference

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

31 March 2020

1 reference

Matrix-embedded cells control osteoclast formation

31 March 2020

1 reference

Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor

31 March 2020

1 reference

The effect of a single dose of osteoprotegerin in postmenopausal women

31 March 2020

1 reference

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

31 March 2020

1 reference

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

31 March 2020

1 reference

Human antibodies from transgenic animals

31 March 2020

1 reference

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

31 March 2020

1 reference

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

31 March 2020

1 reference

Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures.

31 March 2020

1 reference

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.

31 March 2020

1 reference

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats

31 March 2020

1 reference

Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats

31 March 2020

1 reference

Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody

31 March 2020

1 reference

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

31 March 2020

1 reference

Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice

31 March 2020

1 reference

Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice

31 March 2020

1 reference

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

31 March 2020

1 reference

Marked decrease in trabecular bone quality after five years of sodium fluoride therapy--assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients

31 March 2020

1 reference

Metastasis to bone: causes, consequences and therapeutic opportunities

31 March 2020

1 reference

Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors

31 March 2020

1 reference

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

31 March 2020

1 reference

Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases

31 March 2020

1 reference

RANK ligand is a prerequisite for cancer-associated osteolytic lesions

31 March 2020

1 reference

Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis

31 March 2020

1 reference

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

31 March 2020

1 reference

EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases

31 March 2020

1 reference

Osteoprotegerin and rank ligand expression in prostate cancer

31 March 2020

1 reference

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

31 March 2020

1 reference

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

31 March 2020

1 reference

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

31 March 2020

1 reference

Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone.

31 March 2020

1 reference

Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms

31 March 2020

1 reference

The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone

31 March 2020

1 reference

RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis

31 March 2020

1 reference

Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration

31 March 2020

1 reference

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

31 March 2020

1 reference

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

31 March 2020

1 reference

Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis

31 March 2020

1 reference

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

31 March 2020

1 reference

Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats

31 March 2020

1 reference

Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord

31 March 2020

1 reference

The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development

31 March 2020

1 reference

Control of mammary stem cell function by steroid hormone signalling.

31 March 2020

1 reference

Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland.

31 March 2020

1 reference

Progesterone induces adult mammary stem cell expansion

31 March 2020

1 reference

RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini

31 March 2020

1 reference

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

31 March 2020

1 reference

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

31 March 2020

1 reference

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

31 March 2020

1 reference

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling

31 March 2020

1 reference

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes

31 March 2020

1 reference

Regulation of cancer cell migration and bone metastasis by RANKL.

31 March 2020

1 reference

Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin

31 March 2020

1 reference

Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological

31 March 2020

1 reference

Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours

31 March 2020

1 reference

RANK/RANKL: regulators of immune responses and bone physiology

31 March 2020

1 reference

RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla

31 March 2020

1 reference

RANKL Is Necessary and Sufficient to Initiate Development of Antigen-Sampling M Cells in the Intestinal Epithelium

31 March 2020

1 reference

The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance.

31 March 2020

1 reference

The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator.

31 March 2020

1 reference

TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation

31 March 2020

1 reference

Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection

31 March 2020

1 reference

Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses

31 March 2020

1 reference

Regulatory effects of osteoprotegerin on cellular and humoral immune responses

31 March 2020

1 reference

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

31 March 2020

1 reference

Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

31 March 2020

1 reference

Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice

31 March 2020

1 reference

Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.

31 March 2020

1 reference

Central control of fever and female body temperature by RANKL/RANK

31 March 2020

1 reference

Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit

31 March 2020

1 reference

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

31 March 2020

1 reference

Denosumab in postmenopausal women with low bone mineral density

31 March 2020

1 reference

Vertebral fracture assessment using standard bone densitometry equipment predicts incident fractures in women

31 March 2020

1 reference

Beyond hip: importance of other nonspinal fractures.

31 March 2020

1 reference

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

31 March 2020

1 reference

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group

31 March 2020

1 reference

Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk

31 March 2020

1 reference

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

31 March 2020

1 reference

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

31 March 2020

1 reference

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

31 March 2020

1 reference

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

31 March 2020

1 reference

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

31 March 2020

1 reference

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

31 March 2020

1 reference

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

31 March 2020

1 reference

Emerging strategies in bone health management for the adjuvant patient

31 March 2020

1 reference

Mechanisms of bone metastasis

31 March 2020

1 reference

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

31 March 2020

1 reference

Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.

31 March 2020

1 reference

Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

31 March 2020

1 reference

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.

31 March 2020

1 reference

Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity

31 March 2020

1 reference

An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting

31 March 2020

1 reference

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

31 March 2020

1 reference

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

31 March 2020

1 reference

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

31 March 2020

1 reference

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

31 March 2020

1 reference

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

31 March 2020

1 reference

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

31 March 2020

1 reference

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

31 March 2020

1 reference

Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension

31 March 2020

1 reference

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

31 March 2020

1 reference

Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis

31 March 2020

1 reference

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma

31 March 2020

1 reference

12 December 2020

Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.

1 reference

12 December 2020

A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice

1 reference

12 December 2020

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

1 reference

12 December 2020

Heritable disorders of the RANKL/OPG/RANK signaling pathway

1 reference

12 December 2020

Osteoprotegerin diminishes advanced bone cancer pain

1 reference

12 December 2020

Paracrine regulation of osteoclast formation and activity: milestones in discovery.

1 reference

12 December 2020

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

1 reference

12 December 2020

Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.

1 reference

12 December 2020